ORIC Launches Phase 3 Trial, Extends Cash Runway to 2H 2028 with $387.6M

summarizeSummary

ORIC Pharmaceuticals initiated a global Phase 3 trial for rinzimetostat in prostate cancer and reported a cash runway into 2H 2028, with key clinical data readouts expected in the second half of 2026.

check_boxKey Events · Earnings and Guidance · ORIC

• Phase 3 Trial Initiation

  The Himalayas-1 global Phase 3 registrational trial for rinzimetostat in mCRPC is now underway, enrolling approximately 600 patients across 250 sites in 25 countries.

• Bayer Collaboration

  Bayer will supply darolutamide at no cost for the trial, while ORIC retains full global development and commercial rights to rinzimetostat.

• Cash Runway Extended

  With cash and investments of $387.6 million as of June 30, 2026, operations are funded into 2H 2028, beyond the anticipated primary endpoint readout from the first Phase 3 trial.

• Financial Results

  A Q2 2026 net loss of $41.5 million ($0.38 per share) was driven by R&D expenses of $36.3 million, reflecting increased investment in advancing rinzimetostat.

auto_awesomeAnalysis · ORIC · Life Sciences

Advancing its lead candidate rinzimetostat into a global Phase 3 registrational trial for prostate cancer marks a major de-risking event for this clinical-stage biotech. A collaboration with Bayer will supply darolutamide at no cost, while ORIC retains full commercial rights. The $387.6 million cash position provides a runway into the second half of 2028, well beyond the anticipated primary endpoint readout from the first Phase 3 trial, reducing near-term dilution risk. Although the Q2 net loss widened to $41.5 million on higher R&D spending, the cash cushion and upcoming catalysts—including enozertinib data at ESMO in October 2026—position the company for multiple value-creating milestones.